Home

WESEEYOUâ„¢

Intercept’s commitment to research is a commitment to you

The advances we are making in the development of novel treatments for liver diseases such as primary biliary cirrhosis (PBC) and nonalcoholic steatohepatitis (NASH) have the potential to change the lives of patients and physicians who currently have few, if any, therapeutic options.

LEARN ABOUT PBC AND NASH >

News

Thursday, January 29, 2015

Intercept Receives Breakthrough Therapy Designation From FDA for Obeticholic Acid for Nonalcoholic Steatohepatitis (NASH) With Liver Fibrosis
See the press release >